U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Mn.4H2O
Molecular Weight 197.905
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANGANESE CHLORIDE

SMILES

O.O.O.O.[Cl-].[Cl-].[Mn++]

InChI

InChIKey=CNFDGXZLMLFIJV-UHFFFAOYSA-L
InChI=1S/2ClH.Mn.4H2O/h2*1H;;4*1H2/q;;+2;;;;/p-2

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Mn
Molecular Weight 54.938045
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://sites.chem.colostate.edu/diverdi/all_courses/CRC%20reference%20data/solubility%20of%20inorganic%20compounds.pdf | https://www.google.com/patents/DE102016209961A1

Manganese Bromide is a highly water soluble crystalline salt composed of manganese and bromine with the formula MnBr2. Manganese Bromide can be used in place of palladium in the Stille reaction, which couples two carbon atoms using an organotin compound

CNS Activity

Originator

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1447
Activator
1447
Activator
1447
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8583
Unknown

Approved Use

Manganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese.
Primary
Approved
8583
Unknown

Approved Use

Manganese is used for weak bones (osteoporosis).
Palliative
Approved
8583
Unknown

Approved Use

Early research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension.
Curative
Approved
8583
MANGANESE SULFATE

Approved Use

Manganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Primary
Approved
8583
MANGANESE SULFATE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Top-Down Strategy to Synthesize Mesoporous Dual Carbon Armored MnO Nanoparticles for Lithium-Ion Battery Anodes.
2017-04-12
Intramolecular Aminoalkoxylation of Unfunctionalized Olefins via Intramolecular Iodoamination and Aziridinium Ion Ring-Opening Sequence.
2017-04-07
Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats.
2016-11
Yolk-Shell MnO@ZnMn2 O4 /N-C Nanorods Derived from α-MnO2 /ZIF-8 as Anode Materials for Lithium Ion Batteries.
2016-10
Controlled Synthesis of Hollow Manganese Oxide Nanocrystals.
2016-02
Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics.
2014-05
Expression profile analysis of antioxidative stress and developmental pathway genes in the manganese-exposed intertidal copepod Tigriopus japonicus with 6K oligochip.
2013-08
Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain.
2009-09
Manganese inhalation by rhesus monkeys is associated with brain regional changes in biomarkers of neurotoxicity.
2007-06
CsR(R(6)CoI(12))2 (R = Gd, Er) and (CeI)0.26(Ce(6)MnI(9))2: two new structure types featuring R(6)Z clusters.
2006-11-27
Decreased expression of inflammation-related genes following inhalation exposure to manganese.
2006-05
Alterations of oxidative stress biomarkers due to in utero and neonatal exposures of airborne manganese.
2006
Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation.
2005-05
Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism.
2005-03
Bi- and poly-metallic cyanide-bridged complexes of the redox-active cyanomanganese nitrosyl unit [Mn(CN)(PR3)(NO)(eta-C5H4Me)].
2004-02-21
Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin.
2003-01
Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate.
2002-09
Is the axial zero-field splitting parameter of tetragonally elongated high-spin manganese(III) complexes always negative?
2002-07-31
Tetraaqua(1,10-phenanthroline-kappa(2)N,N')manganese(II) sulfate dihydrate.
2002-07
Differential ability of transition metals to induce pulmonary inflammation.
2001-11-15
Equilibrium and kinetics studies of reactions of manganese acetate, cobalt acetate, and bromide salts in acetic acid solutions.
2001-06-18
Manganese citrate chemistry: syntheses, spectroscopic studies, and structural characterizations of novel mononuclear, water-soluble manganese citrate complexes.
2000-09-04
Manganese: brain transport and emerging research needs.
2000-06
Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators.
1999-03-01
Transformation of BALB/c-3T3 cells: IV. Rank-ordered potency of 24 chemical responses detected in a sensitive new assay procedure.
1993-07
Dietary calcium and manganese effects on menstrual cycle symptoms.
1993-05
Effect of quantity and route of administration of manganese monoxide on feed intake and serum manganese in ruminants.
1985-02
Effect of fluoride on copper, manganese and zinc in bone and kidney.
1981-03
Metabolism of l-Tyrosine to 4-Hydroxybenzaldehyde and 3-Bromo-4-Hydroxybenzaldehyde by Chloroplast-containing Fractions of Odonthalia floccosa (Esp.) Falk.
1979-12
Cytochrome oxidase determination using a manganese citrate complex.
1970
Patents

Patents

04048185
23
05089050
24
05261953
23
05629274
23
05700944
23
06136455
24
06548713
23
07091342
25
07384965
26
07544707
26
07598266
24
07615520
24
08460631
23
20020169331
23
20050222440
23
20060205615
24
20060205744
23
20090196809
23
20110203659
23
6589693
23
6627256
23
7435361
26
7687047
23
CA2165259A1
23
CA2517370C
23
DE102016209961
23
EP1627663A3
23
JP 2001058829 A
23
US 3585022 A
23
US20150218342
23
US2825631
23
US2916504
23
US2952519
26

Sample Use Guides

In Vivo Use Guide
Broiler chicks:A basal corn-soybean meal diet (35 ppm Mn) was supplemented with 40, 80, or 120 ppm Mn from Manganese monoxide and fed ad libitum for 21 days.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Naked Manganese monoxide (MnO) nanoparticles had the cytototoxic effect with IC50 value more than 0.1 mg/ml in BRL 3A rat liver cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:09:57 GMT 2025
Edited
by admin
on Mon Mar 31 18:09:57 GMT 2025
Record UNII
QQE170PANO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MANGANESE CHLORIDE
FCC   INCI   ORANGE BOOK   USP   USP-RS   VANDF  
INCI  
Official Name English
MANGANESE CHLORIDE TETRAHYDRATE
JAN   MI   ORANGE BOOK   WHO-DD  
Preferred Name English
MANGANESE CHLORIDE [ORANGE BOOK]
Common Name English
MANGANESE CHLORIDE TETRAHYDRATE [MI]
Common Name English
MANGANESE (AS CHLORIDE) [VANDF]
Common Name English
CMC-001
Code English
MANGANESE CHLORIDE (MNCL2) TETRAHYDRATE
Common Name English
MANGANESE (2+) CHLORIDE TETRAHYDRATE
Systematic Name English
MANGANOUS CHLORIDE
Common Name English
MANGANESE(II) CHLORIDE TETRAHYDRATE
Systematic Name English
MANGANESE DICHLORIDE TETRAHYDRATE
Systematic Name English
MANGANUM MURIATICUM [HPUS]
Common Name English
MANGANESE CHLORIDE [USP MONOGRAPH]
Common Name English
MANGANESE(II) CHLORIDE
Systematic Name English
MANGANESE CHLORIDE TETRAHYDRATE [ORANGE BOOK]
Common Name English
MANGANESE CHLORIDE [USP-RS]
Common Name English
MANGORAL
Brand Name English
MANGANUM MURIATICUM
HPUS  
Common Name English
Manganese chloride tetrahydrate [WHO-DD]
Common Name English
MANGANOUS CHLORIDE TETRAHYDRATE
Common Name English
MANGANESE CHLORIDE [FCC]
Common Name English
MANGANESE CHLORIDE [VANDF]
Common Name English
CMC001
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 342911
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
CFR 21 CFR 184.1446
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
NCI_THESAURUS C29730
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
Code System Code Type Description
DAILYMED
QQE170PANO
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
MERCK INDEX
m7063
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY Merck Index
CAS
13446-34-9
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
EVMPD
SUB27073
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
NCI_THESAURUS
C61823
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
DRUG BANK
DBSALT001361
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
SMS_ID
100000090497
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
RS_ITEM_NUM
1375127
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
PUBCHEM
26003
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
CHEBI
86368
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
MESH
C025340
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
RXCUI
29261
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID00858866
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200693
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
EVMPD
SUB14468MIG
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
WIKIPEDIA
MANGANESE(II) CHLORIDE
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
FDA UNII
QQE170PANO
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
CHEBI
63041
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
DRUG CENTRAL
4521
Created by admin on Mon Mar 31 18:09:57 GMT 2025 , Edited by admin on Mon Mar 31 18:09:57 GMT 2025
PRIMARY
Related Record Type Details
Structure of MANGANOUS CATION
PARENT -> SALT/SOLVATE
Structure of MANGANESE CHLORIDE ANHYDROUS
ANHYDROUS->SOLVATE
Related Record Type Details
Structure of MANGANOUS CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966